Compare · ACAD vs JNJ
ACAD vs JNJ
Side-by-side comparison of ACADIA Pharmaceuticals Inc. (ACAD) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACAD and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $658.24B, about 125.0x ACAD ($5.27B).
- JNJ has been more active in the news (11 items in the past 4 weeks vs 5 for ACAD).
- Both have 25 recent analyst ratings on file.
- Company
- ACADIA Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- $30.59+3.14%
- $273.23+0.07%
- Market cap
- $5.27B
- $658.24B
- 1M return
- +20.53%
- -
- 1Y return
- +18.80%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1985
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 25
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ACAD
- European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
- EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. exercised 20,141 shares at a strike of $17.84 and sold $587,242 worth of shares (20,141 units at $29.16) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by ACADIA Pharmaceuticals Inc.
- ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
- EVP, Head of Research & Dev Thompson Elizabeth H.Z. converted options into 32,272 shares and sold $432,663 worth of shares (16,558 units at $26.13) as part of a pre-agreed trading plan, increasing direct ownership by 479% to 18,994 units (SEC Form 4) (tax withholding)
- Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
- Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
- Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
- Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Latest JNJ
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- CEO and Chairman of the Board Duato Joaquin sold $12,515,010 worth of shares (48,480 units at $258.15), decreasing direct ownership by 15% to 275,967 units (SEC Form 4)
- EVP, Chief Legal Officer Forminard Elizabeth exercised 9,344 shares at a strike of $131.94 and sold $4,090,960 worth of shares (15,918 units at $257.00), decreasing direct ownership by 28% to 16,994 units (SEC Form 4)
- SEC Form 13F-HR filed by Johnson & Johnson
- A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One